Bővebb ismertető
Introduction
Neuropharmacology can be defined simply as the study of drugs that affect nervous tissue. This, however, is not a practical definition since a great many drugs whose therapeutic value is extraneural can affect the nervous system. For example, the cardiotonic drug digitalis will not uncommonly produce central nervous system effects ranging from blurred vision to disorientation. For our purposes we must accordingly limit the scope of neuropharmacology to those drugs specifically employed to affect the nervous system. The domain of neuropharmacology would thus include psychotropic drugs that affect mood and behavior, anesthetics, sedatives, hypnotics, narcotics, anticonvulsants, analeptics, analgetics, and a variety of drugs that affect the autonomic nervous system.
Since, with few exceptions, the precise molecular mechanism of action of these drugs is unknown, and since recitations of their absorption, metabolism, therapeutic indications, and toxic liability can be found in most textbooks of pharmacology, we have chosen to take a different approach to the subject. We will concentrate on the biochemistry and physiology of nervous tissue, emphasizing neurotransmitters, and will introduce the neuropharmacologic agents where their action is related to the subject under discussion. Thus, a discussion of LSD is included in the chapter on serotonin, and a suggested mechanism of action of the antipsychotic drugs is found in Chapter lO.
It is not difficult to justify this focus on either real or proposed neurotransmitters since the drugs act at junctions rather than on the events that occur with axonal conduction or within the cell body. Except for local anesthetics, which interact with axonal membranes, all neuropharmacological agents whose mechanisms of action are to some extent documented seem to be involved primarily with synaptic events. This finding appears quite logical in view of the regulatory mechanisms in the transmission of nerve impulses. The extent to